Herishanu Y, Goldschmidt N, Bairey O, Ruchlemer R, Fineman R, Rahimi-Levene N, Shvidel L, Tadmor T, Ariel A, Braester A, Shapiro M, Joffe E, Polliack A, on behalf of the Israeli CLL Study Group. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. Haematologica [Internet]. 2015May5 [cited 2026Nov.14];100(5):662-9. Available from: https://haematologica.org/article/view/7374